Department of Internal Medicine, Division of Cardiovascular Diseases, University of Tennessee Health Science Center, Memphis, TN, USA.
Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Curr Cardiol Rev. 2022;18(2):e040821195265. doi: 10.2174/1573403X17666210804125939.
Implantable Cardioverter-Defibrillator (ICD) therapy is indicated for patients at risk for sudden cardiac death due to ventricular tachyarrhythmia. The most commonly used risk stratification algorithms use Left Ventricular Ejection Fraction (LVEF) to determine which patients qualify for ICD therapy, even though LVEF is a better marker of total mortality than ventricular tachyarrhythmias mortality. This review evaluates imaging tools and novel biomarkers proposed for better risk stratifying arrhythmic substrate, thereby identifying optimal ICD therapy candidates.
植入式心脏复律除颤器 (ICD) 治疗适用于因室性心动过速而有发生心源性猝死风险的患者。最常用的风险分层算法使用左心室射血分数 (LVEF) 来确定哪些患者有资格接受 ICD 治疗,尽管 LVEF 是总死亡率的一个更好的标志物,而非室性心动过速死亡率的标志物。本综述评估了用于更好地分层心律失常基质风险的成像工具和新型生物标志物,从而确定最佳的 ICD 治疗候选者。